Search results for "Portosystemic encephalopathy"

showing 2 items of 2 documents

Acute and reversible Pisa syndrome as unusual presentation of portosystemic encephalopathy

2020

Abstract We present the first case of acute and reversible Pisa Syndrome, as a clinical manifestation of a portosystemic encephalopathy bout occurring in a patient affected with cirrhosis and clinical-radiological signs of acquired hepatocerebral degeneration, without exposure to psychotropic medications. A 62 year-old man suffering from cirrhosis was admitted to our hospital for sudden onset of mild confusion and postural change. He was observed walking and standing with a tilt toward the right during the last two hours. On neurological examination, he showed bilateral asterixis and extrapyramidal signs. Clinical diagnosis of Pisa Syndrome was made in a setting of raised serum ammonia. A b…

Liver CirrhosisMalemedicine.medical_specialtyCerebellumCirrhosisNeurological examination03 medical and health sciences0302 clinical medicineNeuroimagingAcquired hepatocerebral degenerationInternal medicineBasal gangliaHumansMedicinePortosystemic encephalopathyAsterixisPisa syndrome Axial dystonia Portosystemic encephalopathy Acquired hepatocerebral degeneration Orthotopic liver transplantmedicine.diagnostic_testbusiness.industryParkinsonismOrthotopic liver transplantGeneral MedicineMiddle Agedmedicine.diseaseAxial dystoniaDystoniaPisa syndromeGlobus pallidusmedicine.anatomical_structureHepatic Encephalopathy030220 oncology & carcinogenesisCardiologySurgeryNeurology (clinical)medicine.symptombusiness030217 neurology & neurosurgery
researchProduct

Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy

2019

BACKGROUND Systemic inflammation is a driving force for the development of hepatic encephalopathy and recent studies demonstrated that elevated Interleukin-6 (IL-6) serum levels are associated with the presence of minimal hepatic encephalopathy in patients with liver cirrhosis. AIM To test the hypothesis that IL-6 is a suitable marker to identify patients with liver cirrhosis at high risk for the development of overt hepatic encephalopathy. METHODS 201 patients were included into this prospective cohort study and were followed for a mean time of 322 days. Covert hepatic encephalopathy was diagnosed according to the West-Haven criteria (hepatic encephalopathy grade 1) and with the portosyste…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisSystemic inflammationSensitivity and SpecificityGastroenterologyDiagnosis Differential03 medical and health sciencesLiver disease0302 clinical medicineRisk FactorsInternal medicineHumansMedicinePharmacology (medical)Cumulative incidenceProspective Studies030212 general & internal medicineInterleukin 6Prospective cohort studyPortosystemic encephalopathyHepatic encephalopathyAgedInflammationHepatologybiologyInterleukin-6business.industryGastroenterologyMiddle Agedmedicine.diseaseUp-RegulationC-Reactive ProteinHepatic Encephalopathybiology.proteinFemale030211 gastroenterology & hepatologymedicine.symptombusinessBiomarkersAlimentary Pharmacology & Therapeutics
researchProduct